Ascendis Pharma registers Phase 3 trial of navepegritide and lonapegsomatropin in achondroplasia
The study, led by Ascendis Pharma A/S, plans to enroll 144 participants and start in November 2026. It compares dual therapy with navepegritide and lonapegsomatropin to navepegritide monotherapy and lonapegsomatropin monotherapy in children and adolescents with achondroplasia.
Primary source
ClinicalTrials.gov registry record, November 9, 2026
Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia
Read the source: Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation